EMEA-003134-PIP01-21
Key facts
| Active substance |
Nifurtimox
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0081/2022
|
| PIP number |
EMEA-003134-PIP01-21
|
| Pharmaceutical form(s) |
Tablet
|
| Condition(s) / indication(s) |
Treatment of Chagas disease
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Bayer AG, Leverkusen
E-mail: clinical-trials-contact@bayer.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-003134-PIP01-21
|
| Compliance opinion date |
09/09/2022
|
| Compliance outcome |
positive
|